Massimo Calafiore Sells 10,078 Shares of Orthofix Medical Inc. (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 10,078 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74. Following the transaction, the chief executive officer now owns 133,354 shares in the company, valued at $2,244,347.82. The trade was a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Massimo Calafiore also recently made the following trade(s):

• On Monday, January 13th, Massimo Calafiore sold 9,203 shares of Orthofix Medical stock. The shares were sold at an average price of $17.14, for a total value of $157,739.42.

Orthofix Medical Trading Up 2.5 %

Shares of Orthofix Medical stock opened at $17.94 on Thursday. The company has a market capitalization of $685.56 million, a P/E ratio of -5.73 and a beta of 1.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The company has a fifty day moving average of $18.16 and a 200 day moving average of $16.76. Orthofix Medical Inc. has a fifty-two week low of $12.08 and a fifty-two week high of $20.73.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC purchased a new stake in Orthofix Medical in the 2nd quarter worth about $64,000. Arizona State Retirement System purchased a new position in shares of Orthofix Medical in the 2nd quarter worth approximately $139,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Orthofix Medical by 5.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company’s stock valued at $156,000 after purchasing an additional 559 shares during the last quarter. XTX Topco Ltd purchased a new position in Orthofix Medical during the 2nd quarter worth $175,000. Finally, Assenagon Asset Management S.A. purchased a new position in Orthofix Medical during the 3rd quarter worth $216,000. Institutional investors own 89.76% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on OFIX. Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and raised their price target for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. Roth Mkm restated a “buy” rating and set a $22.00 price target (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Orthofix Medical has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.